Lowenstein Sandler represented Celldex Therapeutics, Inc. in connection with its $200.1 million public offering of common stock underwritten by Jefferies LLC and Leerink Partners LLC as joint book-running managers, Guggenheim Securities, LLC acting as lead manager, and Oppenheimer, Brean Capital, Cantor Fitzgerald and ROTH Capital Partners as co-managers. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Celldex's pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. The Lowenstein team included Anthony O. Pergola, Alan Wovsaniker, Michael J. Lerner, Meredith Prithviraj, Robert J. Paradiso, Michael Amalfe and Eugene Cheval.